Needham Initiates Coverage On Immix Biopharma with Buy Rating, Announces Price Target of $21

Benzinga Newsdesk www.benzinga.com Positive 52.2%

Neg 0% Neu 0% Pos 52.2%

Needham analyst Gil Blum initiates coverage on Immix Biopharma (NASDAQ:IMMX) with a Buy rating and announces Price Target of $21.